Osteoarthritis
Conditions
Brief summary
This study is being conducted on the Vanguard™ Deep Dish Rotating Platform (DD RP) to evaluate the clinical efficacy of the DDRP components.
Detailed description
This study is designed to evaluate the safety and efficacy of Vanguard™ Deep Dish Rotating Platform Knee (mobile bearing knee) as compared to Vanguard Cruciate Retaining Knee (fixed bearing knee). This trial was conducted as the randomised, controlled study. Implant loosening and polyethylene wear in fixed-bearing knee prostheses were recognized as major causes of late failure. The mobile bearing knee have the theoretical advantages of potentially minimizing the polyethylene wear and reducing implant to bone interface stress in order to reduce the incidence of implant loosening. Therefore, the aims of this study were to prove the Vanguard deep dish rotating platform knee is at least as effective in clinical outcome as the widely used current design of knee replacement and better in long term survivorship. The efficacy of the device was determined by the relief of pain, restoration of function and range of motion. The durability of device was determined by the absence of revision/removal and radiological integrity. To assess the safety of the device, all post operative complications were recorded either device related or otherwise. Patient satisfaction was determined by answers to patient outcome questionnaires (Oxford Knee Score, WOMAC and Lower Extremity Activity Scale). Between June 29, 2009 and March 5th 2012, 326 cases were enrolled in the study. In total 117 cases were implanted with the Vanguard fixed bearing cruciate retaining knee; the control arm, and 209 cases were implanted with the Vanguard DDRP. All of these patients fulfilled the inclusion/exclusion criteria. From the 4 participating sites, 2 of them (both located in the Netherlands, Zuyderland Hospital and Bravis Hospital) performed a randomized controlled trial (RCT). In the RCT, 40 cases were assigned to the Trial Arm (Vanguard DDRP), and 51 to the control arm (Vanguard CR). The UK site enrolled cases only in the Vanguard DDRP arm and the French site enrolled in both arms, but non-randomized. Total 326 patients are enrolled in the study.
Interventions
Total knee replacements with the Vanguard Deep Dish Rotating Platform Knee
Total knee replacements with the Vanguard Cruciate Retaining Knee
Sponsors
Study design
Eligibility
Inclusion criteria
* Patients with a pre-operative Knee Society Score of \< 70 * Patients scheduled to undergo primary total knee replacement with any of the following indication: Painful and disabled knee joint resulting from osteoarthritis, Traumatic Arthritis, Rheumatoid Arthritis; One or more compartments are involved * Need to obtain pain relief and improve function * Ability and willingness to follow instructions, including control of weight and activity level, and to return for follow-up evaluations * A good nutritional state of the patient * Full skeletal maturity of the patient, patients who are at least 18 years of age * Patients of either sex * Consent form read, understood, and signed by patient
Exclusion criteria
Absolute contraindications include the following diagnoses: * Patients with a pre-operative Knee Society Score of \>= 70 * Infection * Osteomyelitis * Previous partial or total prosthetic knee replacement on the operative side * Patients who are less than 18 years of age * Sepsis * Patients who had body mass index \>= 40 Relative contraindications include the following factors: * Uncooperative patient or patient with neurological disorders who are incapable of following directions or who are predictably unwilling to return for follow-up examinations * Osteoporosis or marked bone loss, which may preclude proper fixation of the prosthesis * Metabolic disorders, which may impair bone formation * Osteomalacia * Distant foci of infections, which may spread to the implant site * Rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram * Vascular insufficiency, muscular atrophy, or neuromuscular disease in the affected limb. * Incomplete or deficient soft tissue surrounding the knee
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Knee Society Score | 2 years | The Knee Society Score (KSS) is a clinician-completed questionnaire and consists of two sub-scores: an Objective score assessing pain, range of motion, anteroposterior and mediolateral stability, along with deductions for higher than normal flexion contracture, extension lag and/or varus/valgus alignment, and a Function score, assessing walking on level ground and walking up and down stairs, along with deductions for support. Each sub-score can range from 0 to 100 points, with higher scores corresponding to better outcomes, classified as Excellent: 80 - 100 points; Good: 70 - 79 points; Fair: 60 - 69 points; Poor: \< 60 points. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Knee Society Score | 6 weeks, 6 months, annually until all available study patients have completed two-year follow up evaluation and alternating odd years or as needed thereafter up to 10 years | The Knee Society Score (KSS) is a clinician-completed questionnaire and consists of two sub-scores: an Objective score assessing pain, range of motion, anteroposterior and mediolateral stability, along with deductions for higher than normal flexion contracture, extension lag and/or varus/valgus alignment, and a Function score, assessing walking on level ground and walking up and down stairs, along with deductions for support. Each sub-score can range from 0 to 100 points, with higher scores corresponding to better outcomes, classified as Excellent: 80 - 100 points; Good: 70 - 79 points; Fair: 60 - 69 points; Poor: \< 60 points. |
| Radiographic Evaluation: Total Varus Angle | 6 weeks, 6 months, 1, 2, 3, 5, 7, and 10 years postoperative | Assessment of patient x-rays by each site investigator: Total varus angle. This is defined as the sum of the femoral flexion (the angle between the femoral median axis and the tibial median axis) and the tibial angle (the angle between the anatomical axis of the femur and the tibia in the anteroposterior view of the knee joint) minus 180 degrees. |
| Survivorship | 10 years | implant survival at 10 years post surgery and is presented by the number of cases with the implants unrevised |
| Radiographic Evaluation: Radiolucency | 6 weeks, 6 months, 1, 2, 3, 5, 7 and 10 years postoperative | Assessment of patient x-rays by each site investigator: Radiolucency Femoral Radiolucency is defined as the total nr of participants with radiolucency measured on the femur in each of the 7 different zones. Tibia AP Radiolucency is defined as total nr of participants with radiolucency in each of the 7 zones measured in the AP view X-ray Tibia lateral Radiolucency defined as total nr of participants with radiolucency in each of the 3 zones in the lateral view X-ray Patella Radiolucency is defined as total nr of participants with radiolucency in each of the 5 zones |
Countries
France, Netherlands, United Kingdom
Participant flow
Recruitment details
Patients who met the criteria were introduced the study by surgeons and got a written information. By the next visit, the surgeons asked if the patients wanted to participate, and if yes, both signed the informed consent. Dutch sites performed randomized controlled trial (RCT). The UK site enrolled the Vanguard DDRP cases only and the French site enrolled both cases without randomization. The UK site was closed after 3 year follow-up, and the French site became unresponsive in 2020.
Participants by arm
| Arm | Count |
|---|---|
| VG DDRP (Trial Group) This arm utilizes the Vanguard™ Deep Dish Rotating Platform Knee. | 209 |
| VG CR (Control Group) This arm utilizes the Vanguard™ Cruciate Retaining Knee. | 117 |
| Total | 326 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Death | 17 | 6 |
| Overall Study | Lost to Follow-up | 2 | 2 |
| Overall Study | Other | 127 | 75 |
| Overall Study | Study Prosthesis Removed | 12 | 3 |
| Overall Study | Withdrawal by Subject | 10 | 10 |
Baseline characteristics
| Characteristic | VG DDRP (Trial Group) | VG CR (Control Group) | Total |
|---|---|---|---|
| Age, Continuous | 70.1 years | 69.0 years | 69.55 years |
| BMI | 29.7 kg/m² STANDARD_DEVIATION 5.5 | 30.0 kg/m² STANDARD_DEVIATION 4.3 | 29.85 kg/m² STANDARD_DEVIATION 4.9 |
| Race and Ethnicity Not Collected | — | — | 0 Participants |
| Reason for surgery/indication Osteoarthritis | 200 Participants | 115 Participants | 315 Participants |
| Reason for surgery/indication Other | 5 Participants | 0 Participants | 5 Participants |
| Reason for surgery/indication Rheumatoid arthritis | 3 Participants | 2 Participants | 5 Participants |
| Reason for surgery/indication Traumatic arthritis | 1 Participants | 0 Participants | 1 Participants |
| Sex: Female, Male Female | 134 Participants | 67 Participants | 201 Participants |
| Sex: Female, Male Male | 75 Participants | 50 Participants | 125 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 17 / 209 | 6 / 117 |
| other Total, other adverse events | 0 / 209 | 0 / 117 |
| serious Total, serious adverse events | 111 / 209 | 14 / 117 |
Outcome results
Knee Society Score
The Knee Society Score (KSS) is a clinician-completed questionnaire and consists of two sub-scores: an Objective score assessing pain, range of motion, anteroposterior and mediolateral stability, along with deductions for higher than normal flexion contracture, extension lag and/or varus/valgus alignment, and a Function score, assessing walking on level ground and walking up and down stairs, along with deductions for support. Each sub-score can range from 0 to 100 points, with higher scores corresponding to better outcomes, classified as Excellent: 80 - 100 points; Good: 70 - 79 points; Fair: 60 - 69 points; Poor: \< 60 points.
Time frame: 2 years
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| VG DDRP (Trial Group) | Knee Society Score | Objective score | 89.7 score on a scale | Standard Deviation 12 |
| VG DDRP (Trial Group) | Knee Society Score | Function score | 89.9 score on a scale | Standard Deviation 13.9 |
| VG CR (Control Group) | Knee Society Score | Objective score | 91.8 score on a scale | Standard Deviation 9.8 |
| VG CR (Control Group) | Knee Society Score | Function score | 83.2 score on a scale | Standard Deviation 21.6 |
Knee Society Score
The Knee Society Score (KSS) is a clinician-completed questionnaire and consists of two sub-scores: an Objective score assessing pain, range of motion, anteroposterior and mediolateral stability, along with deductions for higher than normal flexion contracture, extension lag and/or varus/valgus alignment, and a Function score, assessing walking on level ground and walking up and down stairs, along with deductions for support. Each sub-score can range from 0 to 100 points, with higher scores corresponding to better outcomes, classified as Excellent: 80 - 100 points; Good: 70 - 79 points; Fair: 60 - 69 points; Poor: \< 60 points.
Time frame: 6 weeks, 6 months, annually until all available study patients have completed two-year follow up evaluation and alternating odd years or as needed thereafter up to 10 years
Population: Numbers of participants for both groups are lower than the enrolled number of patients, especially pre-op. This is because leg extension is not being captured for a lot of pre-op cases, and therefore no score could be calculated.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| VG DDRP (Trial Group) | Knee Society Score | Preop (Objective Score) | 51.2 score on a scale | Standard Deviation 13.7 |
| VG DDRP (Trial Group) | Knee Society Score | 6 Week (Objective Score) | 72.4 score on a scale | Standard Deviation 19.2 |
| VG DDRP (Trial Group) | Knee Society Score | 6 Month (Objective Score) | 81.7 score on a scale | Standard Deviation 15.6 |
| VG DDRP (Trial Group) | Knee Society Score | 1 Year (Objective Score) | 85.8 score on a scale | Standard Deviation 14.8 |
| VG DDRP (Trial Group) | Knee Society Score | 2 Year (Objective Score) | 89.7 score on a scale | Standard Deviation 12 |
| VG DDRP (Trial Group) | Knee Society Score | 3 Year (Objective Score) | 85.4 score on a scale | Standard Deviation 13.7 |
| VG DDRP (Trial Group) | Knee Society Score | 5 Year (Objective Score) | 85.7 score on a scale | Standard Deviation 13.8 |
| VG DDRP (Trial Group) | Knee Society Score | 7 Year (Objective Score) | 86.8 score on a scale | Standard Deviation 12.3 |
| VG DDRP (Trial Group) | Knee Society Score | 10 Year (Objective Score) | 87.6 score on a scale | Standard Deviation 13 |
| VG DDRP (Trial Group) | Knee Society Score | Preop (Function Score) | 51.9 score on a scale | Standard Deviation 17 |
| VG DDRP (Trial Group) | Knee Society Score | 6 Week (Function Score) | 64.1 score on a scale | Standard Deviation 19.9 |
| VG DDRP (Trial Group) | Knee Society Score | 6 Month (Function Score) | 79.8 score on a scale | Standard Deviation 18.7 |
| VG DDRP (Trial Group) | Knee Society Score | 1 Year (Function Score) | 86.6 score on a scale | Standard Deviation 17.4 |
| VG DDRP (Trial Group) | Knee Society Score | 2 Year (Function Score) | 89.9 score on a scale | Standard Deviation 13.9 |
| VG DDRP (Trial Group) | Knee Society Score | 3 Year (Function Score) | 81.3 score on a scale | Standard Deviation 22.1 |
| VG DDRP (Trial Group) | Knee Society Score | 5 Year (Function Score) | 79.8 score on a scale | Standard Deviation 25.1 |
| VG DDRP (Trial Group) | Knee Society Score | 7 Year (Function Score) | 70.5 score on a scale | Standard Deviation 24.8 |
| VG DDRP (Trial Group) | Knee Society Score | 10 Year (Function Score) | 90.0 score on a scale | Standard Deviation 23 |
| VG CR (Control Group) | Knee Society Score | 2 Year (Function Score) | 83.2 score on a scale | Standard Deviation 21.6 |
| VG CR (Control Group) | Knee Society Score | Preop (Objective Score) | 53.2 score on a scale | Standard Deviation 15.8 |
| VG CR (Control Group) | Knee Society Score | Preop (Function Score) | 55.5 score on a scale | Standard Deviation 16.7 |
| VG CR (Control Group) | Knee Society Score | 6 Week (Objective Score) | 77.5 score on a scale | Standard Deviation 16.7 |
| VG CR (Control Group) | Knee Society Score | 10 Year (Function Score) | 88.3 score on a scale | Standard Deviation 23.5 |
| VG CR (Control Group) | Knee Society Score | 6 Month (Objective Score) | 86.4 score on a scale | Standard Deviation 11.1 |
| VG CR (Control Group) | Knee Society Score | 6 Week (Function Score) | 62.7 score on a scale | Standard Deviation 20.3 |
| VG CR (Control Group) | Knee Society Score | 1 Year (Objective Score) | 88.9 score on a scale | Standard Deviation 10.2 |
| VG CR (Control Group) | Knee Society Score | 3 Year (Function Score) | 86.9 score on a scale | Standard Deviation 16.1 |
| VG CR (Control Group) | Knee Society Score | 2 Year (Objective Score) | 91.8 score on a scale | Standard Deviation 9.8 |
| VG CR (Control Group) | Knee Society Score | 6 Month (Function Score) | 78.1 score on a scale | Standard Deviation 16.7 |
| VG CR (Control Group) | Knee Society Score | 3 Year (Objective Score) | 89.5 score on a scale | Standard Deviation 8.5 |
| VG CR (Control Group) | Knee Society Score | 7 Year (Function Score) | 67.9 score on a scale | Standard Deviation 27.7 |
| VG CR (Control Group) | Knee Society Score | 5 Year (Objective Score) | 92.6 score on a scale | Standard Deviation 6.6 |
| VG CR (Control Group) | Knee Society Score | 1 Year (Function Score) | 84.2 score on a scale | Standard Deviation 16.8 |
| VG CR (Control Group) | Knee Society Score | 7 Year (Objective Score) | 90.2 score on a scale | Standard Deviation 6.8 |
| VG CR (Control Group) | Knee Society Score | 5 Year (Function Score) | 90.1 score on a scale | Standard Deviation 12.8 |
| VG CR (Control Group) | Knee Society Score | 10 Year (Objective Score) | 90.6 score on a scale | Standard Deviation 7.6 |
Radiographic Evaluation: Radiolucency
Assessment of patient x-rays by each site investigator: Radiolucency Femoral Radiolucency is defined as the total nr of participants with radiolucency measured on the femur in each of the 7 different zones. Tibia AP Radiolucency is defined as total nr of participants with radiolucency in each of the 7 zones measured in the AP view X-ray Tibia lateral Radiolucency defined as total nr of participants with radiolucency in each of the 3 zones in the lateral view X-ray Patella Radiolucency is defined as total nr of participants with radiolucency in each of the 5 zones
Time frame: 6 weeks, 6 months, 1, 2, 3, 5, 7 and 10 years postoperative
Population: Note that 7 and 10-years radiographic data is limited, this is because the COVID pandemic was impacting those visits. Therefore, the 7 and 10-years information is limited, and results must be interpreted with care.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 1 Year Femoral radiolucency | 14 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 6 Weeks Tibial AP radiolucency | 2 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 6 Weeks Tibial Lateral radiolucency | 3 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 6 Weeks Patella radiolucency | 0 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 6 Weeks Tibial component migration | 2 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 6 Weeks Femoral component migration | 1 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 6 Months Femoral radiolucency | 16 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 6 Months Tibial AP radiolucency | 6 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 6 Months Tibial Lateral radiolucency | 10 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 6 Months Patella radiolucency | 0 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 6 Months Tibial component migration | 2 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 6 Months Femoral component migration | 0 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 6 Weeks Femoral radiolucency | 12 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 1 Year Tibial AP radiolucency | 9 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 1 Year Tibial Lateral radiolucency | 11 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 1 Year Patella radiolucency | 3 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 1 Year Tibial component migration | 1 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 1 Year Femoral component migration | 0 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 2 Year Femoral radiolucency | 4 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 2 Year Tibial AP radiolucency | 4 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 2 Year Tibial Lateral radiolucency | 2 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 2 Year Patella radiolucency | 0 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 2 Year Tibial component migration | 1 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 2 Year Femoral component migration | 0 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 3 Year Femoral radiolucency | 11 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 3 Year Tibial AP radiolucency | 7 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 3 Year Tibial Lateral radiolucency | 5 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 3 Year Patella radiolucency | 1 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 3 Year Tibial component migration | 0 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 3 Year Femoral component migration | 0 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 5 Year Femoral radiolucency | 21 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 5 Year Tibial AP radiolucency | 4 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 5 Year Tibial Lateral radiolucency | 3 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 5 Year Patella radiolucency | 2 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 5 Year Tibial component migration | 3 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 5 Year Femoral component migration | 3 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 7 Year Femoral radiolucency | 14 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 7 Year Tibial AP radiolucency | 7 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 7 Year Tibial Lateral radiolucency | 5 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 7 Year Patella radiolucency | 0 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 7 Year Tibial component migration | 1 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 7 Year Femoral component migration | 0 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 10 Year Femoral radiolucency | 0 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 10 Year Tibial AP radiolucency | 0 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 10 Year Tibial Lateral radiolucency | 0 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 10 Year Patella radiolucency | 0 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 10 Year Tibial component migration | 0 Participants |
| VG DDRP (Trial Group) | Radiographic Evaluation: Radiolucency | 10 Year Femoral component migration | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 10 Year Tibial component migration | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 6 Weeks Femoral radiolucency | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 3 Year Femoral radiolucency | 1 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 6 Weeks Tibial AP radiolucency | 2 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 7 Year Femoral radiolucency | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 6 Weeks Tibial Lateral radiolucency | 1 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 3 Year Tibial AP radiolucency | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 6 Weeks Patella radiolucency | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 10 Year Femoral radiolucency | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 6 Weeks Tibial component migration | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 3 Year Tibial Lateral radiolucency | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 6 Weeks Femoral component migration | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 7 Year Tibial AP radiolucency | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 6 Months Femoral radiolucency | 7 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 3 Year Patella radiolucency | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 6 Months Tibial AP radiolucency | 8 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 10 Year Patella radiolucency | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 6 Months Tibial Lateral radiolucency | 8 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 3 Year Tibial component migration | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 6 Months Patella radiolucency | 1 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 7 Year Tibial Lateral radiolucency | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 6 Months Tibial component migration | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 3 Year Femoral component migration | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 6 Months Femoral component migration | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 10 Year Tibial AP radiolucency | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 1 Year Femoral radiolucency | 6 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 5 Year Femoral radiolucency | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 1 Year Tibial AP radiolucency | 4 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 7 Year Patella radiolucency | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 1 Year Tibial Lateral radiolucency | 6 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 5 Year Tibial AP radiolucency | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 1 Year Patella radiolucency | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 10 Year Femoral component migration | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 1 Year Tibial component migration | 1 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 5 Year Tibial Lateral radiolucency | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 1 Year Femoral component migration | 1 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 7 Year Tibial component migration | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 2 Year Femoral radiolucency | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 5 Year Patella radiolucency | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 2 Year Tibial AP radiolucency | 1 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 10 Year Tibial Lateral radiolucency | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 2 Year Tibial Lateral radiolucency | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 5 Year Tibial component migration | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 2 Year Patella radiolucency | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 7 Year Femoral component migration | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 2 Year Tibial component migration | 1 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 5 Year Femoral component migration | 0 Participants |
| VG CR (Control Group) | Radiographic Evaluation: Radiolucency | 2 Year Femoral component migration | 0 Participants |
Radiographic Evaluation: Total Varus Angle
Assessment of patient x-rays by each site investigator: Total varus angle. This is defined as the sum of the femoral flexion (the angle between the femoral median axis and the tibial median axis) and the tibial angle (the angle between the anatomical axis of the femur and the tibia in the anteroposterior view of the knee joint) minus 180 degrees.
Time frame: 6 weeks, 6 months, 1, 2, 3, 5, 7, and 10 years postoperative
Population: Note that 7 and 10-years radiographic data is limited, this is because the COVID pandemic was impacting those visits. Therefore, the 7 and 10-years information is limited, and results must be interpreted with care.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| VG DDRP (Trial Group) | Radiographic Evaluation: Total Varus Angle | 6 Months Total Valgus Angle | 2.9 Degree | Standard Deviation 3.7 |
| VG DDRP (Trial Group) | Radiographic Evaluation: Total Varus Angle | 6 Weeks Total Valgus Angle | 3.1 Degree | Standard Deviation 3.5 |
| VG DDRP (Trial Group) | Radiographic Evaluation: Total Varus Angle | 1 Year Total Valgus Angle | 3.1 Degree | Standard Deviation 3.7 |
| VG DDRP (Trial Group) | Radiographic Evaluation: Total Varus Angle | 2 Year Total Valgus Angle | 2.9 Degree | Standard Deviation 3.4 |
| VG DDRP (Trial Group) | Radiographic Evaluation: Total Varus Angle | 3 Year Total Valgus Angle | 3.2 Degree | Standard Deviation 4.1 |
| VG DDRP (Trial Group) | Radiographic Evaluation: Total Varus Angle | 5 Year Total Valgus Angle | 2.0 Degree | Standard Deviation 4.2 |
| VG DDRP (Trial Group) | Radiographic Evaluation: Total Varus Angle | 7 Year Total Valgus Angle | -0.7 Degree | Standard Deviation 4.2 |
| VG DDRP (Trial Group) | Radiographic Evaluation: Total Varus Angle | 10 Year Total Valgus Angle | 6.6 Degree | Standard Deviation 4.1 |
| VG CR (Control Group) | Radiographic Evaluation: Total Varus Angle | 10 Year Total Valgus Angle | 3.4 Degree | Standard Deviation 3 |
| VG CR (Control Group) | Radiographic Evaluation: Total Varus Angle | 3 Year Total Valgus Angle | 3.4 Degree | Standard Deviation 3.8 |
| VG CR (Control Group) | Radiographic Evaluation: Total Varus Angle | 6 Weeks Total Valgus Angle | 3.5 Degree | Standard Deviation 3.7 |
| VG CR (Control Group) | Radiographic Evaluation: Total Varus Angle | 6 Months Total Valgus Angle | 3.9 Degree | Standard Deviation 3.2 |
| VG CR (Control Group) | Radiographic Evaluation: Total Varus Angle | 7 Year Total Valgus Angle | 3.0 Degree | Standard Deviation 3 |
| VG CR (Control Group) | Radiographic Evaluation: Total Varus Angle | 1 Year Total Valgus Angle | 3.9 Degree | Standard Deviation 3.3 |
| VG CR (Control Group) | Radiographic Evaluation: Total Varus Angle | 5 Year Total Valgus Angle | 2.3 Degree | Standard Deviation 3.2 |
| VG CR (Control Group) | Radiographic Evaluation: Total Varus Angle | 2 Year Total Valgus Angle | 3.1 Degree | Standard Deviation 2.9 |
Survivorship
implant survival at 10 years post surgery and is presented by the number of cases with the implants unrevised
Time frame: 10 years
Population: The UK site was closed after 3 year follow-up, and the French site became unresponsive in 2020. This explains the low number of long-term follow-up rate.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| VG DDRP (Trial Group) | Survivorship | 178 Participants |
| VG CR (Control Group) | Survivorship | 114 Participants |